These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 27989322

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Factor H Autoantibodies and Complement-Mediated Diseases.
    Zhang Y, Ghiringhelli Borsa N, Shao D, Dopler A, Jones MB, Meyer NC, Pitcher GR, Taylor AO, Nester CM, Schmidt CQ, Smith RJH.
    Front Immunol; 2020; 11():607211. PubMed ID: 33384694
    [Abstract] [Full Text] [Related]

  • 23. Complement and kidney disease.
    Cook HT.
    Curr Opin Nephrol Hypertens; 2013 May; 22(3):295-301. PubMed ID: 23508058
    [Abstract] [Full Text] [Related]

  • 24. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options.
    Sanghera P, Ghanta M, Ozay F, Ariyamuthu VK, Tanriover B.
    Am J Med Sci; 2017 Dec; 354(6):533-538. PubMed ID: 29208248
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Vivarelli M, Barratt J, Beck LH, Fakhouri F, Gale DP, Goicoechea de Jorge E, Mosca M, Noris M, Pickering MC, Susztak K, Thurman JM, Cheung M, King JM, Jadoul M, Winkelmayer WC, Smith RJH, for Conference Participants.
    Kidney Int; 2024 Sep; 106(3):369-391. PubMed ID: 38844295
    [Abstract] [Full Text] [Related]

  • 27. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
    Michels MAHM, van de Kar NCAJ, Volokhina EB, van den Heuvel BLPWJ.
    Methods Mol Biol; 2021 Sep; 2227():83-96. PubMed ID: 33847933
    [Abstract] [Full Text] [Related]

  • 28. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A, Nayer A, Haas CS.
    J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M, Tanabe K.
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Atypical aHUS: State of the art.
    Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ.
    Mol Immunol; 2015 Sep; 67(1):31-42. PubMed ID: 25843230
    [Abstract] [Full Text] [Related]

  • 35. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM, Brophy PD.
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [Abstract] [Full Text] [Related]

  • 36. Inherited Kidney Complement Diseases.
    Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V.
    Clin J Am Soc Nephrol; 2021 Jun; 16(6):942-956. PubMed ID: 33536243
    [Abstract] [Full Text] [Related]

  • 37. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
    Le Clech A, Simon-Tillaux N, Provôt F, Delmas Y, Vieira-Martins P, Limou S, Halimi JM, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-Chiche N, Rondeau E, Frémeaux-Bacchi V, Fakhouri F.
    Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675
    [Abstract] [Full Text] [Related]

  • 38. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.
    Kim MJ, Lee H, Kim YH, Jin SY, Kim HJ, Oh D, Jeon JS.
    BMC Nephrol; 2021 Mar 10; 22(1):86. PubMed ID: 33691638
    [Abstract] [Full Text] [Related]

  • 39. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
    Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K.
    J Am Soc Nephrol; 2018 Apr 10; 29(4):1141-1153. PubMed ID: 29335241
    [Abstract] [Full Text] [Related]

  • 40. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
    Kim JS, Foster KW, Westphal SG.
    Clin Nephrol; 2020 Jan 10; 93(1):51-56. PubMed ID: 31661064
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.